Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Staphylococcal Sepsis, Staphylococcus Aureus Endocarditis

In brief

There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Key facts

Study ID: NCT04886284
Run by: Todd C. Lee MD MPH FIDSA
People needed: 60
Starts: 2024-05-20
Expected to finish: 2027-07-01
Last updated by the study team: 2026-05-27

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adult >=18 years old
S. aureus bacteremia within the past 48 hours:
with any unknown MRSA status (in centers with <15% prevalence of MRSA in their annual blood cultures) or known negative MRSA screening swab within 90 days OR
which has already been shown to be MSSA
Current receipt of cefazolin or where it would be clinically appropriate (according to treating ID specialist) to switch to cefazolin as the backbone therapy (open label, non-study drug).
NOTE: Up to an additional 12-24 hours of open label non-study VANCOMYCIN, LINEZOLID or DAPTOMYCIN may be allowed if there is sepsis and clinical concern for MRSA has not been excluded.

You may not qualify if…

Clinical:
At time of recruitment, the patient has already clinically improved with at least one subsequent negative culture at >24 hours incubation
Anaphylaxis to any beta-lactam antibiotic (and any allergy to ertapenem) Polymicrobial bacteremia (not including skin commensals)
Known seizure disorder
Any receipt of valproic acid
Expected mortality within 48 hours
Need for critical care resources but "do not resuscitate" status precludes the receipt of critical care
Unable to provide informed consent and no available healthcare proxy (with ethics approval for deferred consent in cases of severe illness)
Administrative:
Refusal to provide informed consent
Refusal of healthcare team to participate
No reliable means of outpatient contact (telephone/email/text)
Previously enrolled
Patients whose isolate is identified as MRSA post-enrollment will be subsequently excluded (see below).
Note that because MSSA is much more common than MRSA in Canada (90% of all S. aureus bacteremia at MUHC, for example, are MSSA and in the presence of a negative MRSA screening swab or unknown MRSA status, this means that the risk of MRSA is less than 5%). We believe time to combination therapy is likely linked to benefit, therefore we will recruit the patients as soon as S. aureus is identified but potentially prior to confirmation the organism is MSSA. Where possible, rapid MRSA detection techniques will be deployed; however with conventional screening this will mean approximately a 12-24 hours delay. Organisms subsequently identified as MRSA will be excluded from the intention to treat analysis and the sample size will be adjusted accordingly to ensure the total enrollment meets study goals.

Where it is running

Foothills Medical Centre — Calgary, Alberta, Canada (enrolling)
Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital) — Hamilton, Ontario, Canada (enrolling)
Niagara Health - St. Catharines site — Saint Catharines, Ontario, Canada (enrolling)
Hospital de la Cité de la Sante — Laval, Quebec, Canada (enrolling)
Jewish General Hospital — Montreal, Quebec, Canada (enrolling)
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) — Montreal, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.